NovaGo Logo

Existing Partnerships

Neurimmune Holding AG
Neurimmune is an established leader in the field of recombinant human monoclonal antibody therapeutics, with a track record of creating a strong and sustainable pipeline of programs in various indications. Their most advanced program, the human monoclonal antibody aducanumab, is currently being tested in late-stage clinical trials for the treatment of Alzheimer‘s disease.

NovaGo maintains close collaborations with several world-renowned institutions, including the University of Zurich and the University Hospital Zurich, Switzerland.